CAI NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Caris Life Sciences, Inc. Common Stock · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 15.67 USD
1.0% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -17.9% below the Trend Line and sits at 5.2% of its 52-week range. The latest completed week returned 1.0%, after a -14.4% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is expensive relative to peers. Options positioning is bullish with 42/100 conviction, while the latest news-sentiment score is 55/100. Near-term considerations: earnings are due in 3d.

Setup score 21 out of 100
Latest Close 15.67 USD 31 Jul 2026
1W Return 1.0% latest completed week
4W Return -14.4% short-term follow-through
12W Return -3.0% quarterly tape
Trend Breadth 0.0% 0 of 52 weeks active
Volume Ratio 1.3x vs 13-week average
What is working
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Next-week expectancy is negative at 35.39% based on similar historical setup states.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 1.0% Latest completed week; four-week move -14.4%. Indicator stack 0/48 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 35.39% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Bullish 42/100 conviction; expected move 16.8%. News sentiment 55/100 73 relevant articles in the latest sentiment read. Event risk 3d Next report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -17.9% below the Trend Line and sits at 5.2% of its 52-week range. The latest completed week returned 1.0%, after a -14.4% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.3x the 13-week average. Participation is around or above normal and provides reasonable confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0712-week average 0.05

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure8/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.07Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -14.4% over four weeks, -3.0% over 12 weeks, and -44.1% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W1.0%
4W-14.4%
12W-3.0%
26W-32.3%
52W-44.1%
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.16Latest activity-pressure read.
Pressure change-64.9%Four-week change in activity pressure.
Leadership-40.84Latest relative-leadership reading.
RS change-10.8%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is expensive relative to peers.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 91% Model confidence 87%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength10/100Blend of value, momentum, and quality. Underlying universe rank 91; rank 1 is best.
Value4/100Relative valuation strength. Underlying universe rank 97; rank 1 is best.
Quality94/100Profitability and accounting quality. Underlying universe rank 7; rank 1 is best.
Momentum7/100Medium-term price momentum. Underlying universe rank 94; rank 1 is best.
Growth37/100Revenue and earnings growth. Underlying universe rank 64; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
129.1x
Price divided by trailing earnings.
Price / sales
4.8x
Market value relative to trailing revenue.
EV / EBITDA
35.9x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
4.3%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
68.7%
Gross profit retained from each unit of revenue.
Operating margin
10.0%
Operating profit retained from revenue.
Free-cash-flow margin
18.9%
Free cash flow generated from revenue.
Return on invested capital
33.5%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
6/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-14.8%
Net share repurchases relative to market value.
Shareholder yield
-14.8%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-3.5x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningBullish

CAI shows bullish options pressure with a 42/100 conviction score, put-call volume ratio of 0.42, expected move of 16.8%, and Sharemaestro trend signal inactive.

Conviction42/100
Expected move16.8%
Put/call volume0.42
Pressure48
Speculation43
Volatility96
Trend agreement10
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment55/100

Weighted news tone is neutral across 73 relevant articles.

23 positive · 46 neutral · 4 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings3dNext report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
Options expected move16.8%Nearest-chain priced movement where available.
52-week drawdown-63.1%Distance below the 52-week high.
13-week volatility6.4%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher10 of 2616 weeks finished lower.
Best week+17.2%Week of 17 Apr.
Worst week-12.6%Week of 8 May.
Latest week+1.0%Week of 31 Jul.

Shape of recent returns

Strong gains5
Modest gains5
Flat weeks0
Modest losses4
Sharp losses12
Recent vol6.4%13-week weekly-return volatility.
Base vol7.7%52-week weekly-return volatility.
Up/down split21/31Count of positive and negative weeks in the 52-week window.
Average skew6.8% / -6.0%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape21/100

Trend, activity pressure, participation, and risk combine to a 21/100 tape read.

 Indicator analysis24/100

Latest 12-week confirmation: trend 0/12, activity pressure 8/12, relative leadership 0/12.

Activity pressure 0.07; No reversal markers Next-Week ExpectancyNegative 35.39%

Next-week expectancy is negative with a 35.39% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors29/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 89; Small Cap Core rank 99 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options45/100

CAI shows bullish options pressure with a 42/100 conviction score, put-call volume ratio of 0.42, expected move of 16.8%, and Sharemaestro trend signal inactive.

Bullish · Call-side pressure · Expected move 16.8% Sentiment55/100

Weighted news tone is neutral across 73 relevant articles.

Caris Life Sciences Inc (CAI) Risk Assessment: Volatility, Financial Risk & Investment Risk Insiders50/100

No recent insider transaction evidence is stored.

 Earnings3d

Next report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202615.67 USD1.0%19.08 USD24.32 USD0.16-40.8420.8MOff
24 Jul 202615.52 USD-5.9%19.46 USD24.46 USD0.26-41.9015.4MOff
17 Jul 202616.49 USD-2.9%19.88 USD24.62 USD0.48-40.1321.3MOff
10 Jul 202616.99 USD-7.2%20.26 USD24.77 USD0.43-41.7413.7MOff
3 Jul 202618.30 USD-1.1%20.59 USD24.91 USD0.46-36.8514.6MOff
26 Jun 202618.50 USD0.2%20.94 USD25.03 USD0.38-36.2819.2MOff
19 Jun 202618.47 USD2.8%21.17 USD25.15 USD0.18-39.898.1MOff
12 Jun 202617.97 USD9.0%21.36 USD25.28 USD0.11-40.7013.9MOff
5 Jun 202616.49 USD-1.4%21.56 USD25.43 USD-0.04-13.9MOff
29 May 202616.72 USD7.5%21.86 USD25.60 USD-0.08-8.8MOff
22 May 202615.55 USD6.9%22.31 USD25.79 USD-0.11-14.9MOff
15 May 202614.55 USD-9.9%22.82 USD26.00 USD-0.16-22.0MOff
8 May 202616.15 USD-12.6%23.39 USD26.24 USD-0.24-17.3MOff
1 May 202618.47 USD-8.6%23.87 USD26.46 USD-0.58-9.4MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.